Otonomy Inc

NASDAQ:OTIC   9:59:36 AM EDT
1.81
-0.06 (-3.21%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

OTONOMY, INC. Stock, NASDAQ:OTIC

4796 EXECUTIVE DRIVE, SAN DIEGO, CA 92121
United States of America
Phone: (619) 323-2200
Number of Employees: 49

Description

Otonomy, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for diseases and disorders of the ear in the United States. It offers OTIPRIO, a ciprofloxacin otic suspension for use during tympanostomy tube placement surgery in pediatric patients. OTIPRIO has also completed a Phase III clinical trial for treating swimmer's ear and a Phase II clinical trial for treating acute otitis media with tubes. The company also develops OTO-104, a sustained-exposure formulation of the steroid dexamethasone in Phase III clinical trial for the treatment of Meniere's disease and other inner ear conditions; and OTO-311, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which has completed a Phase 1 clinical safety trial for the treatment of tinnitus. Otonomy, Inc. was founded in 2008 and is headquartered in San Diego, California.